REG-FDA-Wegovy-MACE-2024 — FDA Cardiovascular Risk Reduction Approval

[DRAFT — authored 2026-04-20. FDA press release URL and date verified 2026-04-20.]

Source

US Food and Drug Administration. "FDA Approves First Treatment to Reduce Risk of Serious Heart Problems Specifically in Adults with Obesity or Overweight." Press announcement, March 8, 2024.

External URLs:

Regulatory Action

On March 8, 2024, the FDA approved a new indication for Wegovy (semaglutide 2.4 mg weekly SC):

"To reduce the risk of cardiovascular death, heart attack and stroke in adults with cardiovascular disease and either obesity or overweight."

This made Wegovy the first and only medication indicated for both chronic weight management AND major adverse cardiovascular event (MACE) reduction in adults with established CVD + overweight/obesity.

Evidence Base

SELECT trial (PMID 37952131, Lincoff AM et al., NEJM 2023): multinational, multicenter, placebo-controlled Phase 3 trial, n=17,604 adults with CVD + overweight/obesity without T2D, randomized to semaglutide 2.4 mg weekly SC vs placebo
MACE reduction: 6.5% (semaglutide) vs 8.0% (placebo) — 20% relative risk reduction; absolute risk reduction 1.5% at 40 months
Participants in both arms received standard-of-care medical treatment + healthy lifestyle counseling

Indication Language (FDA-approved label)

Wegovy is indicated in addition to a reduced-calorie diet and increased physical activity for:

Reducing the risk of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke in adults with established cardiovascular disease + either obesity (BMI ≥30 kg/m²) or overweight (BMI ≥27 kg/m²)

Clinical Relevance

This approval represents the first indication-specific FDA endorsement of an obesity medication for cardiovascular prevention — a paradigm shift from viewing obesity pharmacotherapy as cosmetic/QoL-focused to disease-modifying. Core teaching points:

First-in-class MACE indication: Not just a claim in label warnings; a full FDA-approved indication. Supports payer coverage conversations for secondary CV prevention use.
Mechanism insight: CV benefit in SELECT was independent of baseline adiposity and magnitude of weight loss (see SELECT 4-year long-term analysis, PMID 38740993) — suggesting direct anti-inflammatory, endothelial, and metabolic mechanisms beyond weight reduction.
Guideline-level change: ADA 2025/2026, AACE 2025, EASO 2025 guidelines incorporated this indication into their recommendations for obesity + ASCVD.
Subsequent expansion: The MACE indication predated later label expansions — MASH (August 2025), 7.2 mg higher-dose (March 2026), oral Wegovy 25 mg (August 2025).

Linked Peptides

Semaglutide

Related Lessons

Lesson 5.2 — Semaglutide Deep Dive (cardiovascular indication)
Lesson 5.4 — Regulatory timeline

Related Notes

PMID-37952131 – SELECT Cardiovascular Outcomes Trial — pivotal trial
PMID-38740993 – SELECT 4-Year Long-term Weight Loss Ryan — durability extension
REG-FDA-Wegovy-Label-2025-2026 – Current FDA Prescribing Information — current label
PMID-39222642 – Kosiborod 4-Trial Pooled HF Lancet 2024 — pooled HF analysis (SELECT + FLOW + STEP-HFpEF + STEP-HFpEF DM)

REG-FDA-Wegovy-MACE-2024 – Cardiovascular Risk Reduction Approval